SEC Tracker
Get the app
TNXP · XBRL financial data

Tonix Pharmaceuticals Holding financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (TNXP's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024†Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers3,9893,779*2,4822,2082,8222,582*2,4291,9983,2905,390*6,87813,544
Cost of revenue2,3742,367*1,6603,3671,5551,183*9433,2721,3671,058*1,578703
Research and development21,05017,120*12,8639,6989,1148,297*7,43610,8209,28916,941*18,21319,417
Selling, general and administrative8,71211,621*9,3107,5027,70715,582*10,10416,20225,70135,677*28,62435,959
Operating income (loss)(28,147)(27,329)*(21,351)(77,316)(15,554)(22,480)*(16,054)(28,296)(33,067)(48,286)*(41,537)(42,535)
Interest income1727*——181*394—1,2311,344*1,346—
Interest expense————301280*———0*——
Other income (expense)1727*(593)(605)(327)(554)*394(1,955)(1,156)(39)*(3)(49)
Net income (loss)(27,975)(27,322)*(14,939)(78,776)(14,213)(22,108)*(16,829)(28,272)(32,010)(46,910)*(40,194)(40,552)
Earnings per share, basic USD per share(1.83)—(0.18)(19.28)(0.23)—(2.84)(3.86)(3.59)—(2.93)(2.44)
Earnings per share, diluted USD per share(1.83)—(0.18)(19.28)(0.23)—(2.84)(3.86)(3.59)—(2.93)(2.44)
Weighted average shares, basic thousands of shares15,328—80,8794,08562,122—5,9277,3278,923—13,70716,635
Weighted average shares, diluted thousands of shares15,328—80,8794,08562,122—5,9277,3278,923—13,70716,635
  • † Share count changed about 1/29 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (TNXP's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024†Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents6,91424,9487,0494,15628,23398,776131,716125,331190,055207,637185,470176,232
Accounts receivable———3,3394,0133,6833,3122,3203,4816,2718,82011,805
Inventory13,31713,63912,3519,4577,9318,408——————
Prepaid and other current assets9,5449,18110,6988,33510,3668,1356,4099,8988,8068,9559,23310,717
Total current assets31,33747,76830,09825,28750,543119,002149,573143,535208,071228,876207,168203,432
Property and equipment, net94,86694,02893,05843,24742,74742,25241,76642,33542,57444,45644,89444,760
Right-of-use asset1,0818247576926285655014383761,5441,4451,346
Goodwill965965965—————————
Total assets139,282154,457135,34370,30794,989162,890192,870187,359252,440277,171257,912254,088
Accounts payable7,7993,7826,64910,4063,9354,5464,1937,7838,5408,1149,6499,051
Current portion of long-term debt—2,3502,8202,8202,8202,820——————
Total current liabilities17,73318,88420,47922,04315,18118,30712,14619,06121,03130,83729,64730,785
Long-term debt—6,5616,1585,6685,1724,667——————
Lease liability, non-current7166325634934253583282972661,1841,1281,022
Total liabilities18,44948,93227,20028,20420,77823,33212,47419,35821,29732,02130,77531,807
Accumulated deficit(573,336)(600,658)(615,597)(694,373)(708,586)(730,694)(747,523)(775,795)(807,805)(854,715)(894,909)(935,461)
Total stockholders' equity120,833105,525108,14342,10374,211139,558180,396168,001231,143245,150227,137222,281
Total liabilities and equity139,282154,457135,34370,30794,989162,890192,870187,359252,440277,171257,912254,088
Common shares outstanding (cover page) thousands of shares23,84984,49195,54422,004186,8946,4357,3258,76611,77713,40515,94117,151
  • † Share count changed about 1/29 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (TNXP's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024†Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(27,975)(27,322)*(14,939)(78,776)(14,213)(22,108)*(16,829)(28,272)(32,010)(46,910)*(40,194)(40,552)
Stock-based compensation2,079*2,038*1,6921,154*1,038*894*8821,423*1,923*1,789*1,9702,256*
Depreciation and amortization1,216*1,261*1,2101,205*510*496*493483*461*488*555619*
Net cash from operating activities(23,385)*(22,340)*(17,575)(9,919)*(18,801)*(14,630)*(16,579)(14,833)*(28,782)*(39,650)*(42,318)(42,243)*
Purchases of property and equipment1,813*438*1080*9*3*6527*962*1,874*1,692587*
Net cash from investing activities(821)*(431)*(108)0*(9)*(3)*(6)(2,539)*(962)*(1,021)*(1,692)(587)*
Proceeds from issuing common stock6,274*9,200*——43,606*85,859*62,23013,895*94,861*66,954*20,12633,489*
Share repurchases0*0*————3,0472,9020*7,811*——
Repayments of long-term debt——235705*705*705*9,6500*0*0*——
Net cash from financing activities6,274*40,714*(212)7,025*42,905*85,154*49,53310,993*94,861*59,143*20,20533,505*
Net change in cash(17,944)*17,933*(17,899)(2,893)*24,078*70,545*32,939(6,383)*65,113*18,458*(23,799)(9,389)*
  • † Share count changed about 1/29 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Tonix Pharmaceuticals Holding176,23213,544(42,243)*17.2M4.2 quarters 10-QJun 30, 2026
Abeona Therapeutics56,22911,380(17,496)*57.2M8.4 quarters 10-QJun 30, 2026
Vanda Pharmaceuticals61,93369,815(28,435)*60.5M1.7 quarters 10-QSep 30, 2026
Ocugen100,0511,488(12,198)*339.1M8.2 quarters 10-QJun 30, 2026
Atea Pharmaceuticals76,548not reported(37,084)*80.2M5.9 quarters 10-QJun 30, 2026
Verastem136,35340,078(43,909)*90.6M3.1 quarters 10-QJun 30, 2026
Standard Biotools267,48719,385(6,161)*394.8M21.6 quarters 10-QSep 30, 2026
Aquestive Therapeutics90,3497,557(7,046)*125.7M8.4 quarters 10-QSep 30, 2026
Corvus Pharmaceuticals18,905not reported(15,398)*84.1M14.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.